Location:none, DK
Speaker:Tomas Ussing
Primary Industry:Health & Medical Devices
Executive Summary:FluimediX will provide a microfluidic platform – The NanoCycler™ - enabling the identification of SNPs in a portable environment, based on polymer disposables. The emerging market of pharmacogenetics relates to the understanding of genetically determined drug-response. Recent advances within genetic research have paved the way to an understanding of the influence of specific genetic variations on drug metabolism. We will target FDA validated biomarkers in the Cytocrome P450 enzyme group, thus taking a regulatory short cut to market. Initially we will address the administration of psychiatric drugs for the following reasons: · Lack of efficacy leads to a “trial and error” process that takes months to conclude. · Side effects arising from erroneous dose are the number one reason for patients terminating treatment. Elements of our technology utilises soon-to-expire 3’rd party IPR. This aspect creates a perfect “window of opportunity” in relation to our development period. Additionally - by the very nature of our technologies - we are able to “circumvent” 3’rd party IPR (e.g. Multiplex and Hot-Start PCR)
Venture is:B-Round


Corporate Presentations:

  • Air Products
  • BASF
  • Eastman Kodak Company
  • Genzyme
  • Goodrich
  • Hewlett-Packard
  • Honda
  • Medtronic
  • Merck
  • Sanyo

Reserved Presentations:

  • ExxonMobil
  • IBM

Partnering Events:
(full access included)

Platinum Sponsor

University of Hawaii

Press Sponsor

Business Wire

Commercialization Partner



Invest Australia AzTE Technology Enterprises

Media Sponsors

(joint with Nanotech 2007) Nature
Red Herring

Supporting Organizations

Boston University
Midwest Research University Network


“A major challenge for both the technology and the financial communities is finding a forum in which all parties can interact and explore possibilities for future innovation. TechConnect was created to fill this void, bringing both sides together under one roof into a setting that ultimately will help significant ground-breaking concepts come to life.”
Matthew Laudon, Co-Founder and Director of TechConnect